Protein News and Research RSS Feed - Protein News and Research

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. [More]
Study compares carbon footprint of Mediterranean diet with UK and US menus

Study compares carbon footprint of Mediterranean diet with UK and US menus

The health benefits of the Mediterranean diet are well-known. As well as being healthier, a recent article concludes that the menu traditionally eaten in Spain leaves less of a carbon footprint than that of the US or the United Kingdom. [More]
New Autism-Causing Genetic Variant Identified

New Autism-Causing Genetic Variant Identified

Using a novel approach that homes in on rare families severely affected by autism, a Johns Hopkins-led team of researchers has identified a new genetic cause of the disease. The rare genetic variant offers important insights into the root causes of autism, the researchers say. And, they suggest, their unconventional method can be used to identify other genetic causes of autism and other complex genetic conditions. [More]
Metabolic imbalance can trigger respiratory diseases in early childhood

Metabolic imbalance can trigger respiratory diseases in early childhood

An imbalance in our metabolism can trigger inflammatory processes in the body and activate the immune system. In a recent study, published in the Journal of Allergy and Clinical Immunology, UFZ researchers have been able to show that this applies even to newborns and children under one year of age, and is correlated with the development of respiratory diseases in early childhood. [More]
Transition announces positive results from ELND005 AME and renal clearance studies

Transition announces positive results from ELND005 AME and renal clearance studies

Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development. [More]
UVA researchers develop compound that could lead to improved leukemia treatments

UVA researchers develop compound that could lead to improved leukemia treatments

Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved treatments in people. The researchers call it an exciting "new paradigm" for treating leukemia. [More]
Immunotherapy reverses memory problems in animal model of Alzheimer's disease

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March 25 issue of the Journal of Neuroscience. [More]
UCLA-led team validates first standardized protocol for tracking early signs of Alzheimer's disease

UCLA-led team validates first standardized protocol for tracking early signs of Alzheimer's disease

After six years of painstaking research, a UCLA-led team has validated the first standardized protocol for measuring one of the earliest signs of Alzheimer's disease -- the atrophy of the part of the brain known as the hippocampus. [More]
BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin. [More]
Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. [More]
Vermillion announces total revenue of $1.6 million for fourth quarter 2014

Vermillion announces total revenue of $1.6 million for fourth quarter 2014

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter ended and full year ended December 31, 2014. [More]
Migraine headaches with auras may increase risk of stroke

Migraine headaches with auras may increase risk of stroke

People who suffer migraine headaches with auras are at roughly double the risk of suffering the most common type of stroke. [More]
Biological clue could help explain why some drinkers can't resist alcohol

Biological clue could help explain why some drinkers can't resist alcohol

Virginia Commonwealth University School of Medicine researchers have discovered a biological clue that could help explain why some drinkers develop a dependence on alcohol and others do not. [More]
Brain-somatic-activating mutations in MTOR cause focal cortical dysplasia type II

Brain-somatic-activating mutations in MTOR cause focal cortical dysplasia type II

Epilepsy is a brain disorder that afflicts more than 50 million people worldwide. Many epilepsy patients can control their symptoms through medication, but about 30% suffer from intractable epilepsy and are unable to manage the disease with drugs. Intractable epilepsy causes multiple seizures, permanent mental, physical, and developmental disabilities, and even death. [More]
Mexican researcher close to finding a cure for Parkinson's disease

Mexican researcher close to finding a cure for Parkinson's disease

Parkinson's disease, which took world fame after being diagnosed in various personalities such as actor Michael J. Fox, the heavyweight champion Muhammad Ali and the painter Salvador Dalí, could be very close to a cure, thanks to a Mexican researcher which managed to eliminate its neurological effects with an immunosuppressant. [More]
First randomized, controlled trial of pharmacotherapy in PCD patients now in place

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

Primary ciliary dyskinesia (PCD) is a rare, genetic respiratory tract disorder leading to progressive pulmonary dysfunction. It exhibits many problems typical for orphan diseases: delayed diagnosis, limited evidence-based knowledge etc. The European Union is funding BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) to introduce uniform guidelines for PCD treatment and diagnosis across Europe. [More]
University of Michigan scientists grow first 3D mini lungs from human stem cells

University of Michigan scientists grow first 3D mini lungs from human stem cells

Scientists from the University of Michigan have grown the first 3D mini lungs from stem cells. The study, published in eLife, compliments other developments in the field such as growing mainly 2D structures and building lung tissue from the scaffold of donated organs. [More]
Study explains why COPD patients develop tolerance to roflumilast drug

Study explains why COPD patients develop tolerance to roflumilast drug

Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly results in patients developing a tolerance to the drug after repeated use and makes the drug less effective, according to researchers at Georgia State University, Kumamoto University and the University of Rochester Medical Center. [More]
ItpkB enzyme regulates stem cells function to prevent cancer, anemia

ItpkB enzyme regulates stem cells function to prevent cancer, anemia

Stem cells can generate any type of cell in the body, but they are inactive most of the time--and for good reason. When stem cells become too active and divide too often, they risk acquiring cell damage and mutations. [More]
Researchers find Pom1 protein regulates different processes of cell growth and division

Researchers find Pom1 protein regulates different processes of cell growth and division

Investigators from Dartmouth's Norris Cotton Cancer Center led by James Moseley, PhD have found that the protein Pom1 possesses the ability to modify different sets of proteins to coordinate the processes of cell growth and division. [More]
Advertisement
Advertisement